KeraFAST Revenue and Competitors
Estimated Revenue & Valuation
- KeraFAST's estimated annual revenue is currently $775k per year.
- KeraFAST's estimated revenue per employee is $155,000
Employee Data
- KeraFAST has 5 Employees.
- KeraFAST grew their employee count by -29% last year.
KeraFAST's People
Name | Title | Email/Phone |
---|---|---|
1 | Logistics Manager | Reveal Email/Phone |
2 | Customer Service Manager | Reveal Email/Phone |
KeraFAST Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is KeraFAST?
At Kerafast, our mission is to make unique laboratory-made research tools easily accessible to the global scientific community. Our portfolio includes cell lines, antibodies, small molecules, dyes and more, many of which are not available elsewhere. Since our founding in 2011, researchers from more than 170 institutions worldwide have made their innovative reagents available through our online platform, where the materials can be quickly accessed without needing to go through the traditional Material Transfer Agreement process. We handle all selling and shipping logistics for the providing laboratory, as well as return generous royalty payments from every sale. We therefore help providing labs save time and resources, while generating extra funding for further research. Procuring scientists can more easily discover and access unique reagents that are often unavailable elsewhere, while also funding the work of other researchers. This creates a global community of scientists contributing and accessing Reagents for the Greater Good to accelerate their own research as well as scientific progress overall. In 2018, Kerafast merged with Absolute Antibody, a UK-based company with a vision to make recombinant antibody technology available to all researchers. The merger brought together two companies with a shared commitment to improving the selection of research tools available to the scientific community.
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
-29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KeraFAST News
... were infected with VSV-G pseudotyped ?G-luciferase (G*?G-luciferase, Kerafast) at a multiplicity of infection (MOI) of 3 for 2 hours.
Kerafast; Beijing Strong Biotechnologies; Pointe Scientific; Luxcel Biosciences; Randox Laboratories; Beijing Leadman Biochemistry; Shenzhen...
... (Hokkaido University, Japan) and were originally obtained from the American Tissue Culture Collection (ATCC) and Kerafast, respectively.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 5 | -17% | $30.2M |
#2 | $0.1M | 5 | -37% | $50.8M |
#3 | $0.1M | 5 | 0% | $26.2M |
#4 | $0.1M | 5 | -17% | $48.8M |
#5 | $0.1M | 5 | 0% | $7.8M |